AZ Acquires Chinese Cell Therapy Pharma Company for 1.6 Trillion KRW
Global pharmaceutical company AstraZeneca (AZ) is acquiring Gracell Biotechnologies, a Chinese cell therapy developer, for up to $1.2 billion (approximately 1.6 trillion KRW).
On the 26th (local time), AZ announced that Gracell Biotechnologies, a Nasdaq-listed clinical-stage biopharmaceutical company, is developing innovative cell therapies.
According to AZ, Gracell Biotechnologies' candidate drug 'GC012F' has potential as a treatment for blood cancers and autoimmune diseases. AZ stated, "This acquisition will complement our existing capabilities and investments in cell therapy," adding, "AZ has established a strong position in the CAR-T (chimeric antigen receptor T-cell) therapy field targeting solid tumors."
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Kim Young-hoon, the Problem Solver Who Averted Samsung Electronics' General Strike... Breakthrough Achieved Through the Power of Dialogue
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
AZ initially acquired $1 billion worth of shares in Gracell Biotechnologies and plans to purchase an additional $200 million in shares upon reaching certain regulatory milestones.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
